A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. [clinicaltrials:NCT00002199]
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. [clinicaltrials:NCT00002199]
Bio2RDF identifier
NCT00002199
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002199
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To compare the safety, ...... ic and phenotypic resistance.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase III Randomized Double- ...... oviral Therapy-Naive Subjects.
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
In this international s ...... navir, 1592U89, and Combivir.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Anti-HIV Agents
Drug Resistance, Microbial
Drug Therapy, Combination
HIV Protease Inhibitors
Lamivudine
Reverse Transcriptase Inhibitors
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-06-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002199
official title [clinicaltrials_vocabulary:official-title]
A Phase III Randomized Double- ...... oviral Therapy-Naive Subjects.
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
secondary id [clinicaltrials_vocabulary:secondary-id]
CNAA/B3005
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
1998-11-01T00:00:00Z
identifier
clinicaltrials:NCT00002199
title
A Phase III Randomized Double- ...... oviral Therapy-Naive Subjects.
@en
type
label
A Phase III Randomized Double- ...... . [clinicaltrials:NCT00002199]
@en